ArticlePediatric endocrinology, diabetes, and metabolism2025
Primary hyperparathyroidism in children: Insights from a single-center cohort.
Article in Pediatric endocrinology, diabetes, and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Hyperparathyroidism in the Pediatric Population: Surgical Considerations and Outcomes: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary hyperparathyroidism (PHPT) is a rare endocrine disorder in children, often presenting with symptomatic hypercalcemia and end-organ damage. AIM OF THE STUDY: We aim to describe the clinical features, treatment outcomes, and follow-up of pediatric PHPT patients at a tertiary center in Portugal. MATERIAL AND
methodsA retrospective study including all patients under 18 years diagnosed with PHPT between 2012 and 2024. Data on demographics, clinical features, laboratory results, imaging studies, genetic testing, surgical outcomes, and follow-up were collected and analyzed.
resultsSix patients (66.6% male) with a median age of 16 years (range: 9-17) were included. Half of the patients (n = 3) presented with symptoms, including bone pain and nephrolithiasis. A genetic mutation was identified in 50% of cases: 2 patients with MEN 1 and 1 patient with CDC73 mutation. Ultrasound and Tc99m-sestamibi scans demonstrated high concordance (80%) for adenoma localization. Of the four patients who underwent surgery, all had solitary adenomas, achieving biochemical cure with a median follow-up of 103 months. Postoperative complications were minimal, with transient hypocalcemia in 2 patients and one case of hungry bone syndrome. No cases of persistent or recurrent PHPT were observed.
conclusionsSolitary parathyroid adenoma is the leading cause of pediatric PHPT. Surgical treatment is highly effective and safe, with excellent cure rates and few complications. Genetic testing and individualized imaging strategies are crucial for optimal management. Larger studies are needed to establish evidence-based guidelines for pediatric PHPT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.